Acadian Asset Management LLC Invests $1.35 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Acadian Asset Management LLC acquired a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,566 shares of the biotechnology company’s stock, valued at approximately $1,353,000.

Several other large investors also recently modified their holdings of SRPT. Riggs Asset Managment Co. Inc. grew its holdings in Sarepta Therapeutics by 33.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 75 shares during the period. GAMMA Investing LLC grew its holdings in Sarepta Therapeutics by 37.0% in the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 87 shares during the period. Cambridge Investment Research Advisors Inc. grew its holdings in Sarepta Therapeutics by 1.9% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock worth $1,000,000 after purchasing an additional 120 shares during the period. WCM Investment Management LLC grew its holdings in Sarepta Therapeutics by 2.3% in the first quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock worth $813,000 after purchasing an additional 142 shares during the period. Finally, Innealta Capital LLC acquired a new stake in Sarepta Therapeutics in the second quarter worth $31,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on SRPT shares. Needham & Company LLC restated a “buy” rating and issued a $235.00 price target on shares of Sarepta Therapeutics in a report on Thursday, June 27th. William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. BMO Capital Markets lifted their price objective on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Monday, June 24th. Piper Sandler reduced their price objective on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Finally, Leerink Partners lifted their price objective on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, June 24th. Three analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $186.22.

Insider Transactions at Sarepta Therapeutics

In other news, insider Bilal Arif sold 7,859 shares of Sarepta Therapeutics stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the transaction, the insider now owns 21,261 shares in the company, valued at $3,467,243.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the transaction, the insider now directly owns 21,261 shares of the company’s stock, valued at approximately $3,467,243.88. The disclosure for this sale can be found here. Insiders sold 52,801 shares of company stock worth $8,399,586 over the last quarter. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $124.65 on Monday. The firm has a market cap of $11.89 billion, a price-to-earnings ratio of 1,133.18 and a beta of 0.81. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90. Sarepta Therapeutics, Inc. has a 52 week low of $55.25 and a 52 week high of $173.25. The firm’s 50-day simple moving average is $139.78 and its two-hundred day simple moving average is $132.71.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.01 by $0.06. The business had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.27) earnings per share. As a group, equities analysts forecast that Sarepta Therapeutics, Inc. will post 1.47 earnings per share for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.